Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
Cyclo Therapeutics (CYTH) Stock Price & Analysis
189 Followers
CYTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $2.57
Previous Close$1.41
Volume16.47K
Average Volume (3M)95.30K
Market Cap
$40.49M
Enterprise Value$38.73M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$45.23K
Price to Earnings (P/E)-1.1
Beta1.67
Next Earnings
Aug 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding28,715,740
10 Day Avg. Volume31,444
30 Day Avg. Volume95,296
Standard Deviation0.23
R-Squared0.00141
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)8.45
Price to Sales (P/S)29.43
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.69
Enterprise Value/Gross Profit27.67
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$3.20Price Target Upside123.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cyclo Therapeutics News
PremiumPre-Earnings
Is CYTH a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCyclodextrin-based therapies are showing promise in treating rare neurological disorders, with positive early-stage trial results indicating potential for significant breakthroughs.
Regulatory MilestoneThe company's lead clinical candidate for treating Niemann-Pick Disease Type C has been granted Fast Track designation by the FDA, accelerating the potential path to market.
Strategic PartnershipsThe recent merger with Applied Molecular Transport is poised to bolster the company's financial strength and operational capabilities, enhancing its market position.
Bears Say
Clinical Trial ProgressThe progress of the Phase 2b study for Alzheimer’s Disease is contingent upon securing sufficient funding.
Financial HealthCyclo Therapeutics has approximately 5-6 months of cash runway, which puts the company in a position where it may soon need to secure additional funding.
Financial ResultsCyclo reported a net loss of $5.6M and ended the period with $9.2M in cash on the balance sheet.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
CYTH FAQ
What was Cyclo Therapeutics’s price range in the past 12 months?
Cyclo Therapeutics lowest stock price was $0.89 and its highest was $2.57 in the past 12 months.
What is Cyclo Therapeutics’s market cap?
Currently, no data Available
When is Cyclo Therapeutics’s upcoming earnings report date?
Cyclo Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is in 89 days.
How were Cyclo Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cyclo Therapeutics overvalued?
According to Wall Street analysts Cyclo Therapeutics’s price is currently Undervalued.
Does Cyclo Therapeutics pay dividends?
Cyclo Therapeutics does not currently pay dividends.
What is Cyclo Therapeutics’s EPS estimate?
Cyclo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclo Therapeutics have?
Cyclo Therapeutics has 28,715,740 shares outstanding.
What happened to Cyclo Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyclo Therapeutics?
Currently, no hedge funds are holding shares in CYTH
---
Cyclo Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.20 (123.78% Upside)
$3.20 (123.78% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.52%
12-Months-Change
Fundamentals
Return on Equity
-730.48%
Trailing 12-Months
Asset Growth
214.28%
Trailing 12-Months
Company Description
Cyclo Therapeutics
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
---
CYTH Stock 12 Month Forecast
Average Price Target
$3.20
▲(123.78% Upside)
Technical Analysis
Best Analysts Covering CYTH
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-28.66%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -28.66% per trade.
---